PRODUCTION OF HUMAN ANNEXIN A5 FUSED WITH BACTERIAL ADENOSINE CATABOLIC ENZYMES (13-17)

Архив в PDF формате
Дата публикации статьи в журнале: 2020/11/18
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 62, Том: 1, Страницы в выпуске: 13-17
Автор: Bulatovski A.B.
, Institute of Microbiology, National Academy of Sciences of Belarus , Master of biology, junior researcher
Автор: Zinchenko A.I.
, Institute of Microbiology, National Academy of Sciences of Belarus , Dr. Sci, Professor, head of laboratory
Анотация: Submerged culture of recombinant Escherichia coli strains produced chimeric proteins «AnnexinADase» and «Annexin-PNPase» composed of human annexin A5, fused with homologous adenosine deaminase and purine nucleoside phosphorylase of E. coli, respectively. Affinity chromatographic isolation of these proteins from ultrasonic cell lysates on Ni2+-NTA-agarose yielded preparations of 95% purity grade (according to the results of polyacrylamide gel electrophoresis). The chimeric proteins «Annexin-ADase» and «Annexin-PNPase» have been shown to transform adenosine into adenine and inosine, respectively. Such properties of the target proteins, judging by literature data, allow to consider them as promising agents for use in cancer biotherapy.
Ключевые слова: fusion protein   human annexin A5   adenosine deaminase   purine nucleoside phosphorylase   Escherichia coli  
Данные для цитирования: Bulatovski A.B. , Zinchenko A.I. , . PRODUCTION OF HUMAN ANNEXIN A5 FUSED WITH BACTERIAL ADENOSINE CATABOLIC ENZYMES (13-17). Восточно Европейский Научный Журнал. Биологические науки. 2020/11/18; 62(1):13-17.

Список литературы: 1. Zugazagoitia J., Guedes C., Ponce S., et al. Current challenges in cancer treatment // Clinical Therapeutics. 2016. Vol. 38, N 7. P. 1551–1566. DOI: https://doi.org/10.1016/j.clinthera.2016.03.026 2. Ventola C.L. Cancer Immunotherapy, Part 1: Current Strategies and Agents // PT. 2017. Vol. 42, N 6. P. 375–383. 3. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020 // CA Cancer J. Clin. 2020. Vol. 70. P. 7–30. 4. American Cancer Society. Cancer Facts and Figures 2020 [Electronic resource]. Mode of access: https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/annual-cancerfacts-and-figures/2020/cancer-facts-and-figures- 2020.pdf 5. Pan C., Liu H., Robins E., et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy // Journal of Hematology & Oncology. 2020. Vol. 13, N 1.:29. DOI: 10.1186/s13045-020-00862-w 6. Cancer – the second most frequent cause of death of Belarusians [Electronic resource]; 2016. Mode of access: https://news.tut.by/society/483467.html. Date of access: 30.07.2020. 7. Kushlinskii N.E., Nemtsova M.V. Molecular biological characteristics of cancer // Annals of the Russian Academy of Medical Sciences. 2014. N 1–2. P. 5–15. https://doi.org/10.15690/vramn.v69.i1-2.934 8. Sverdlov E.D. Multidimensional complexity of cancer. Simple solutions are needed // Biochemistry (Mosc). 2016. Vol. 81, N 7. P. 731–738. DOI: 10.1134/s0006297916070099 9. Coley W.B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus) // Proc. R. Soc. Med. 1910. Vol. 3(Surg Sect). P. 1–48. 10. Nauts H.C., Fowler G.A., Bogatko F.H. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man // Acta Medica Scandinavica. Supplementum. 1953. Vol. 276. P. 1–103. 11. Hoption Cann S.A., van Netten J.P., van Netten C. Dr William Coley and tumour regression: a place in history or in the future // Postgrad. Med. J. 2003. Vol. 79, N 938. P. 672–680. 12. Giraldo N.A., Sanchez-Salas R., Peske J.D., et al. The clinical role of the TME in solid cancer // Brit. J. Cancer. 2019. Vol. 120, N 1. P. 45–53. DOI: 10.1038/s41416-018-0327-z 13. Joshi S. Targeting the tumor microenvironment in neuroblastoma: Recent advances and future directions // Cancers. 2020. Vol. 12, N 8. Art. 2057. DOI: 10.3390/cancers12082057 14. Vaupel P., Mayer A. Hypoxia-driven adenosine accumulation: A crucial microenvironmental factor promoting tumor progression // Adv. Exp. Med. Biol. 2016. Vol. 876. P. 177–183. DOI: 10.1007/9781-4939-3023-4_22 15. Zinchenko A.I. Adenosine as a potential target for cancer biotherapy // Proc. Nat. Acad. Sci. Belarus: Biol. Ser. 2016. N 4. P. 118–128 (in Russian). 16. Wang J., Liu J., Cao Y., Hu M., Hua Z. Domain IV of Annexin A5 is critical for binding calcium and guarantees its maximum binding to the phosphatidylserine membrane // Molecules. 2017. Vol. 22, N 12. Art. 2256. DOI: 10.3390/molecules22122256 17. Sharma B., Kanwar S.S. Phosphatidylserine: A cancer cell targeting biomarker // Semin. Cancer Biol. 2018. Vol. 52, Pt 1. P. 17–25. DOI: 10.1016/j.semcancer.2017.08.012 18. Kang T.H., Park J.H., Yang A., et al. Annexin A5 as an immune checkpoint inhibitor and tumorhoming molecule for cancer treatment // Nat. Commun. 2020. Vol. 11, N 1. Art. 1137. DOI: 10.1038/s41467- 020-14821-z 19. Krais J.J., De Crescenzo O., Harrison R.G. Purine nucleoside phosphorylase targeted by Annexin V to breast cancer vasculature for enzyme prodrug therapy // PLoS ONE. 2013. Vol. 8, N 10. Art. e76403. DOI: 10.1371/journal.pone.0076403 20. Zinchenko A.I., Kvach S.V., Eroshevskaya L.A., Bulatovski A.B. Engineering of bacterial strainproducer of chimeric protein containing human annexin A5 and Escherichia coli adenosine deaminase // East. Eur. Sci. J. 2017. N 4. P. 5‒11. 21. Bulatovski A.B., Zinchenko A.I. Creation of strain-producer of bacterial purine nucleoside phosphorylase fused with human annexin A5 // Proc. Nat. Acad. Sci. Belarus: Biol. Ser. 2020. Vol. 65, N 2. P. 239–244 (in Russian). https://doi.org/10.29235/1029-8940-2020-65-2-239- 244 22. Bertani G. Lysogeny at mid-twentieth century: P1, P2, and other experimental systems // J. Bacteriol. 2004. Vol. 186, N 3. P. 595–600. DOI: 10.1128/JB.186.3.595-600.2004 23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 // Nature. 1970. Vol. 227, N 5259. P. 680–685.